Status
Conditions
Treatments
About
Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Macular oedema due to diabetic retinopathy, vascular occlusion and other retinal disorders.
Full description
Purpose: To study the efficacy and safety of invitreal injection of bevacizumab (avastin) in all the following conditions.
American Academy of ophthalmology-Risk management recommendations for off-label , Intravitreal use of Avastin.
Included indications, exclusion criteria, possible complications and the off-label status of the drug.
Best corrected visual acuity, Fundus Photography, anterior segment examination, Optical coherence tomography and in selected patients Electrophysiology, VEP and Fundus fluorescein angiography was done according to surgeons discretion.
All the patients were examined on day 1, 1st week and subsequently depending on the surgeons discretion and tests were performed during follow ups.
During follow up best-corrected visual acuity, anterior and posterior segment examination. Fundus photography, Intraocular pressure and OCT was repeated and in selected patients FFA, ERG,and VEP was done, physicians follow up was done.
Preparation of the Drug:
Bevacizumab Avastin (Avastin) comes in a sterile vial (100 mg in 4 ml) preservative free and ensure safety the vial injection was within a day.
Injections were given with 30 gauge needle, tuberculin syringes single use. 0.05ml containing 1.25 mg drug was given intravitreally under all aseptic precautions under topical anaesthesia,suggested by Flynn , Harry w.and scott, Ingrid u. -Evolving guidelines for intravitreous injections.
Following the injection topical antibiotics was given for 1 week.
Design: Prospective interventional non randomised case series.
Informed consent process
Informed consent was taken in English and the patients were explained in their local language by the treating surgeon.
The Food and Drug Administration approved Avastin for the treatment of metastatic Colorectal cancer. It is the first humanized Anti-VEGF antibody, which prevents angiogenesis. Since the drug is FDA approved the off-label drug is used for Intravitreal usage. For other purposes if patients are well-informed about the product, base, its use on firm scientific method and sound medical evidence, and maintain records of its use and effects. Ophthalmologists are using Avastin "off-label" to treat AMD and similar conditions since research indicates that VEGF is one of the causes for the growth of the abnormal vessels that cause these conditions. All the patients were informed about the "off-label" status, which is not FDA approved. Similar to kenalog, which is FDA approved but the off-label drug is used as Intravitreal injection to treat eye conditions.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Central trial contact
shubha anil; sivakami pai, MS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal